Clinical Trials Logo

Filter by:
NCT ID: NCT05761626 Completed - Clinical trials for Acute Respiratory Distress Syndrome

Mechanical Power and Ventilatory Ratio in ARDS

Start date: March 1, 2016
Phase:
Study type: Observational

Mechanical power (MP) and ventilatory ratio (VR) are variables associated with outcomes in patients with acute respiratory distress syndrome (ARDS). In respiratory setting, the optimization of MP should lead to an increase in VR. Therefore, the objectives of this study are: to assess the relationship between MP and VR and to compare the components of MP (ventilatory variables) according to a level of MP (17 J/minute) considered harmful.

NCT ID: NCT05752201 Completed - COVID-19 Vaccine Clinical Trials

ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine

ARVAC-F2/3
Start date: February 6, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The goals of this clinical trial are: 1. Phase 2: to test a gamma adapted recombinant vaccine against SARS-CoV-2 in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus. 2. Phase 3 (first volunteer enrollement on March 25, 2023): to test a recombinant vaccine against SARS-CoV-2 comparing three different versions (Gamma Variant RBD-based ARVAC-CG vaccine, Omicron Variant RBD-based ARVAC-CG vaccine, Bivariant Gamma/Omicron RBD-based ARVAC-CG vaccine), in adult volunteers previously vaccinated against the SARS-CoV-2 virus The main questions to be answered are: 1. Phase 2: 1. What si the immune response after one dose of vaccine? 2. What is the safety and tolerability profile of this vaccine? 2. Phase 3 : 1. What is the immune response triggered by each vaccine formulation against Wuhan, gamma, and omicron variants. 2. What is the safety and tolerability profile of this vaccine? In phase 2, participants will receive one dose of the study vaccine and one dose of placebo 28 days apart, in a cross-over design. In phase 3 (not yet recruitment), participants will be randomized to receive one of the three possible types of vaccines and all of them will receive one dose of the corresponding vaccine and 1 dose of placebo 28 days apart, in a cross over design.

NCT ID: NCT05747846 Completed - Clinical trials for Carpal Tunnel Syndrome

Pain in Carpal Tunnel Release Wide-awake Local Anesthesia With no Tourniquet vs Local Anesthesia With Tourniquet

Start date: December 15, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to compare pain, satisfaction, and experience between patients who underwent Carpal Tunnel Release with wide-awake local anesthesia no tourniquet technique and local anesthesia with a tourniquet.

NCT ID: NCT05697276 Completed - Clinical trials for Carpal Tunnel Syndrome

Are There Differences in Postoperative Pain Between Bupivacaine and Lidocaine for Carpal Tunnel Release?

Start date: September 13, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the use of bupivacaine and lidocaine as local anesthetics in carpal tunnel release surgery. The main questions it aims to answer are: - Are there any differences in pain after surgery? - Are there any differences in postoperative analgesic consumption?

NCT ID: NCT05656508 Completed - COVID-19 Vaccine Clinical Trials

ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine

Start date: April 20, 2022
Phase: Phase 1
Study type: Interventional

The objective of this clinical trial is to test a new vaccine against SARS-CoV-2 (ARVAC-CG) in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus. The main questions it aims to answer are: - What is the safety and tolerability profile of the two-dose schedule of this new vaccine? - What is the immune response after each dose of vaccine Participants will receive two doses of the study vaccine 28 days apart. They will be required to complete a total of 7 safety and immunogenicity follow-up visits over a 1-year period.

NCT ID: NCT05638737 Completed - Clinical trials for Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

A Study in Participants With Non-cirrhotic NASH With Fibrosis

COSMOS
Start date: October 26, 2022
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. Participants will be in the trial for up to 24 weeks, including a screening period lasting up to 8 weeks, a 12-week treatment period, and a 4-week safety follow-up period Participants are not expected to directly benefit from treatment during this trial. Participants will help researchers learn more about and how to develop AZD4831 to treat NASH.

NCT ID: NCT05619042 Completed - Atherosclerosis Clinical Trials

Detection of Coronary Artery Calcifications by Whole Blood Transcriptome Analyzed by Artificial InTelligence Algorithms

CAC-TRAIT
Start date: November 7, 2022
Phase:
Study type: Observational

The goal of this observational study is to determine the diagnostic accuracy of peripheral whole blood transcriptomes analyzed by an artificial intelligence algorithm to detect the presence and extent of coronary calcification in individuals without a history of known cardiovascular disease. The main question it aims to answer is: 1. Will the proposed method predict the presence and extent of coronary artery calcification from the peripheral whole-blood transcriptomes?

NCT ID: NCT05598242 Completed - Dry Eye Syndromes Clinical Trials

Amniotic Membrane Treatment for Hyposecretory Dry Eye

Start date: February 1, 2019
Phase: Phase 3
Study type: Interventional

The goal of this randomized, active-controlled, parallel-group trial is to evaluate the clinical efficacy of amniotic membrane extract eye drops (AMEED) in reducing signs and symptoms of hyposecretory dry eye Participants will receibed amniotic membrane extract eye drops 6 times daily and was evaluated at baseline day and day 30th. Researchers will compare against autologous serum eye drops effects

NCT ID: NCT05590403 Completed - Clinical trials for Respiratory Syncytial Virus Infections

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Start date: October 28, 2022
Phase: Phase 3
Study type: Interventional

The aim of this study is to demonstrate the non-inferiority (NI) of the immune response and evaluate safety of RSVPreF3 older adults (OA) investigational vaccine in adults 50-59 years of age (YOA), including those who are at increased risk (AIR) of respiratory syncytial virus (RSV)-lower respiratory tract disease (LRTD), versus adults >=60 YOA

NCT ID: NCT05577520 Completed - Clinical trials for Maxillary Sinus Augmentation

Maxillary Sinus Augmentation Using Different Size Bovine Bone Particles

Start date: March 1, 2016
Phase: N/A
Study type: Interventional

The decrease in maxillary alveolar ridge bone volume and sinus pneumatization are a challenge to implant-assisted prosthetic rehabilitation. Guided bone regeneration using bone substitutes is an adequate alternative for maxillary sinus augmentation. Objective: To histologically and histomorphometrically compare bone repair response to 250 to 1000 µm and 1000 to 2000 µm anorganic bovine bone mineral (ABBM) particles as bone substitute in maxillary sinus augmentation (MSA).